anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject skin cosmetic making the troubled skin condition such as atopic dermatitis normal, having effects for improving or preventing atopic symptoms, and useful as a facial cleansing cosmetic, facial lotion or the like, by including an ingredient such as a ceramide and a maltose/sucrose condensate. SOLUTION: This skin cosmetic is obtained by including (A) pref. 0.001-5.0 wt.%, more pref. 0.01-2.0 wt.%, of one or two kind(s) of ingredients selected from glycoceramides such as a ceramide and a glucoceramide and (B) pref. 0.001-5.0 wt.%, more pref. 0.01-2.0 wt.%, of a maltose/sucrose condensation product. The compounding weight ratio of the ingredient A to the ingredient B is desirable to be 0.001 to 10.0. This skin cosmetic is useful as a facial milky lotion, cream, pack or the like.
Adherence to the Mediterranean diet (MedDiet) has long been associated with several health benefits, including a reduced risk of heart disease, diabetes, and obesity. The MedDiet is characterized by a high consumption of foods such as fruits, vegetables, whole grains, fish, and olive oil, along with a moderate intake of red meat and red wine with meals. Some studies report significant differences between men and women in susceptibility to obesity, with women at a higher prevalence of obesity than men. One unexplored aspect, however, concerns the sex difference in MedDiet adherence, which could be influenced by various factors, such as health perceptions, food preferences, and cultural influences. The aim of this study is to assess the effectiveness and impact of MedDiet adherence in men and women, with a focus on its influence on health and well-being, as well as its ability to promote sex equity in healthcare outcomes. Moreover, we aim to measure the overall health improvements in men and women participating in a MedDiet program, including changes in body composition and overall quality of life. This study highlights that the MedDiet is associated with more significant body weight loss in women, although their increase in MedDiet adherence was lower than in men. Trial registration: NCT01890070. Registered 24 June 2013.
Chronic pain is often accompanied by tissue damage and pain hypersensitivity. It easily relapses and is challenging to cure, which seriously affects the patients' quality of life and is an urgent problem to be solved. Current treatment methods primarily rely on morphine drugs, which do not address the underlying nerve injury and may cause adverse reactions. Therefore, in recent years, scientists have shifted their focus from chronic pain treatment to cell transplantation. This review describes the classification and mechanism of chronic pain through the introduction of the characteristics of olfactory ensheathing cells (OECs), an in-depth discussion of special glial cells through the phagocytosis of nerve debris, receptor-ligand interactions, providing nutrition, and other inhibition of neuroinflammation, and ultimately supporting axon regeneration and mitigation of chronic pain. This review summarizes the potential and limitations of OECs for treating chronic pain by objectively analyzing relevant clinical trials and methods to enhance efficacy and future development prospects.
A 5-year-old girl with limping gait, presented with right-sided buttock and lower extremity pain and numbness. There was a history of trauma preceding this eighteen months ago. There was diffuse decreased sensation to pinprick and light touch but mainly from above the right knee joint. The rest of the clinical examination was normal. The patient attended 20 sessions, which were structured to include High-frequency transcutaneous neuromuscular electrical nerve stimulation (TENS), chiropractic care, strengthening exercise for hamstring and back muscle and gait training (figure 1). Electrical stimulation was performed for 30 min /day for five days a week for four consecutive weeks, 100 Hz frequency with pulse duration 200 m sec with an (on-off) (20 sec stimulation, 20 sec pause) and maximum amplitude 40 - 60 mA. Two electrodes were placed on the back at the level of L5, S1 lumber spine and the other two electrodes were placed along the course of sciatic nerve on the back of the thigh. Chiropractic treatment sessions (manual manipulation refers to a high-velocity, short lever arm thrust that is applied to abnormal vertebra with the goal of improving functionality, reducing nerve irritability and restoring range of motion in the back) were scheduled for one month with frequency 5 sessions per week. strengthening program was three sets, ten repetitions and rest period of 1-2 minutes for low intensity or low repetition activity started by 2-3 days a week, then increase to 3-5 days a week as the strength progresses, amount of resistance 40%-60% of one-repetition maximum (1 RM). Mirror imaging and verbal promoting, Balance training and coordination to encourage normal gait.

EMG examination using concentric needle electrodes was carried bilaterally for the vastus medialis, tibialis anterior, extensor digitorum brevis and abductor halluces muscles and the right biceps femoris muscle. Motor conduction studies were carried out for both common peroneal, tibial and right main trunk of the right sciatic nerve.
The parent study KEEPS, will be a randomized, placebo-controlled double blinded, prospective trial with two active groups and one placebo group. Only patients enrolled in KEEPS will be invited to participate in this ancillary study.Duration of the KEEPS study will be for 4 years after randomization for each study subject, with assessment of the primary endpoint, carotid CIMT, twice at baseline, 12, 24, 36 and 48 months. Ancillary to the KEEPS study, patients will undergo holter monitoring at baseline, 24 and 48 months.Data will be analyzed after 24 and 48 months (corresponding to data analysis of the primary endpoints.) Holter monitors will be put on during the scheduled KEEPS visits, will be worn for 24 hours and will be returned the following day. Effects of estrogen on heart rate variability (HRV) and repolarization parameters will be evaluated, and also correlated with clinical, quality of life, sleep and mood information gathered through the parent study. Anticipated enrollment from the parent study at this site is 90 study subjects. This ancillary does not involve the use of drugs or investigational devices.
PURPOSE:A soft capsule, prepared by filling a solution containing nifedipine, given amounts of polyalkylene glycol, polyvinyl pyrrolidone and tocopherol in a capsule containing a dye absorbing ultraviolet light, having improved storage stability, and easily dissolvable and absorbable. CONSTITUTION:A nifedipine soft capsule prepared by filling a solution containing 1pt.wt. nifedipine, 10-50pts.wt. polyalkylene glycol having 200-600 average molecular weight, 0.1-5pts.wt. polyvinyl pyrrolidone and 0.001-0.1pts.wt. tocopherol in a capsule containing a dye absorbing light of 250-460nm wavelength, e.g. food red No.2 or No.3 of food yellow No.4. A capsule composition generally used for soft capsules, e.g. a mixture of 100pts.wt. gelatin with 38-60pts.wt. glycerol, is used as the capsule material. The dye is preferably incorporated in the capsule material in an amount of 0.5wt% or more, particularly 0.5-5wt%, based on the capsule material.
PROBLEM TO BE SOLVED: To obtain a new pyridine-based compound useful as a medicine inhibiting a human.telomerase as a ribonucleic protein enzyme relating to human.telomere DNA synthesis and telomerase activity. SOLUTION: This pyridine-based telomerase inhibitor is a compound expressed by formula I [X1 is O or S; R1 is Yn R6  (n) is 0-10; when (n)Ε0, Y is methylene, etc.; R6 is an alkyl or the like}; R2 is H, an alkyl, cyano or the like; R3 and R4 are each H, amino, an alkylamino or the like; R5 is an alkyl iminyl, a phenyl iminyl or the like.] or its pharmacologically permissible salt, e.g. a compound of formula II in which X1 is S, R2 is cyano, R3 and R4 are each H, R5 is 3-methyl-2-pyridyliminyl and L is ethylene. The compound of the formula I is obtained by, for instance, transforming 2-thio-3- cyano-6-(dimethoxymethyl)pyridine to 2-thioether with an alkylation agent in the presence of a base and removing an acetal group to give an aldehyde compound, then reacting with an amine or a hydrazine derivative.
Participants underwent a single application of the 0.20% CHX gel. Samples were collected in basal conditions (i.e., before application) and at 5 minutes, 1 hour, 3 hours, 5 hours and 7 hours after application.
Background: The clinical spectrum of acute myocardial infarction complicated by cardiogenic shock (AMICS) varies. Out-of-hospital cardiac arrest (OHCA) can be the first sign of cardiac failure, whereas others present with various degrees of hemodynamic instability (non-OHCA). The aim of the present study was to explore differences in prehospital management and characteristics of survivors and nonsurvivors in AMICS patients with OHCA or non-OHCA. Methods: Data analysis was based on patient data from the RETROSHOCK cohort comprising consecutive AMICS patients admitted to two tertiary cardiac centers between 2010 and 2017. Results: 1,716 AMICS patients were included and 42% presented with OHCA. Mortality in OHCA patients was 47% versus 57% in the non-OHCA group. Almost all OHCA patients were intubated before admission (96%). In the non-OHCA group, prehospital intubation (25%) was associated with a better survival ( P < 0.001). Lactate level on admission demonstrated a linear relationship with mortality in OHCA patients. In non-OHCA, probability of death was higher for any given lactate level <12 mmol/L compared with OHCA. However, a lactate level >7 mmol/L in non-OHCA did not increase mortality odds any further. Conclusion: Mortality was almost doubled for any admission lactate level up to 7 mmol/L in non-OHCA patients. Above this level, mortality remained unchanged in non-OHCA patients but continued to increase in OHCA patients. Prehospital intubation was performed in almost all OHCA patients but only in one of four patients without OHCA. Early intubation in non-OHCA patients was associated with a better outcome.
The invention concerns inventive nanoparticles (NPs), their compositions and their use as therapeutic agents in particular in the field of oncology and/or as imaging agents. The NPs are composed of first nanoparticles of at least one high-Z metal oxide material, to which smaller second nanoparticles are covalently bonded at the first nanoparticles' surface. The second nanoparticles are composed of either a) at least one noble metal or at least one metal oxide, metal sulfide, metal selenide or metal sulfide/selenide that is a Fenton or Fenton-like reaction catalyst. The inventive NPs generate a surprisingly therapeutic effect when exposed to ionizing radiation such as X-Rays, γ-Rays, protons, neutrons, radioactive isotopes and/or electron beams. Thus, the NPs may be used as radioenhancers in the field of oncology. The nanoparticles may also be used as contrast agents.
PURPOSE: To study the long-term clinical outcome and treatment strategies of recurrent and chronic non-infectious anterior uveitis.
METHODS: Multicenter study of anterior uveitis patients from 2001 to 2022. Outcome measures included ocular complications, medical and surgical therapies, and visual acuity measured at the beginning of follow-up and at 1, 2, and 5 years thereafter.
RESULTS: In total, 76 patients were included, with a mean follow-up of 6.8 years. Idiopathic anterior uveitis was the most common etiology (56%). Immunomodulatory agents (IMAs) were used in almost half of the cohort. Early initiation of IMAs was associated with a lower risk of developing glaucoma ( P = 0.019). Mean best corrected visual acuity (BCVA) improved after 5 years in both groups. Early use of immunomodulation was correlated with a better visual outcome at 2 years ( P = 0.024).
CONCLUSION: Chronic and recurrent anterior uveitis were associated with greater risk than expected for ocular complications, surgeries, and vision impairment. Early initiation of immunomodulation should be strongly considered to improve clinical course and outcome.
The Ubiquitin Specific Peptidase 22 (USP22), a component of the Spt-Ada-Gcn5 Acetyltransferase (SAGA) histone modifying complex, is overexpressed in multiple human cancers, but how USP22 impacts tumorigenesis is not clear. We reported previously that Usp22 loss in mice impacts execution of several signaling pathways driven by growth factor receptors such as erythroblastic oncogene B b2 (ERBB2). To determine whether changes in USP22 expression affects ERBB2-driven tumorigenesis, we introduced conditional overexpression or deletion alleles of Usp22 into mice bearing the Mouse mammary tumor virus-Neu-Ires-Cre (MMTV-NIC) transgene, which drives both rat ERBB2/NEU expression and Cre recombinase activity from the MMTV promoter resulting in mammary tumor formation. We found that USP22 overexpression in mammary glands did not further enhance primary tumorigenesis in MMTV-NIC female mice, but increased lung metastases were observed. However, deletion of Usp22 significantly decreased tumor burden and increased survival of MMTV-NIC mice. These effects were associated with markedly decreased levels of both Erbb2 mRNA and protein, indicating Usp22 loss impacts MMTV promoter activity. Usp22 loss had no impact on ERBB2 expression in other settings, including MCF10A cells bearing a Cytomegalovirus (CMV)-driven ERBB2 transgene or in human epidermal growth factor receptor 2 (HER2)+ human SKBR3 and HCC1953 cells. Decreased activity of the MMTV promoter in MMTV-NIC mice correlated with decreased expression of known regulatory factors, including the glucocorticoid receptor (GR), the progesterone receptor (PR), and the chromatin remodeling factor Brahma-related gene-1 (BRG1). Together our findings indicate that increased expression of USP22 does not augment the activity of an activated ERBB2/NEU transgene but impacts of Usp22 loss on tumorigenesis cannot be assessed in this model due to unexpected effects on MMTV-driven Erbb2/Neu expression.
Objectives: Cervical cancer prevention practices are desperately low in the Caribbean. This study aims to describe the cervical cancer stigma and to evaluate the influence of the prevention practices among the Caribbean non-patient population in Jamaica, Grenada, Trinidad and Tobago. Methods: A cross-sectional study involving 1,207 participants was conducted using a culturally trans-created Cancer Stigma Scale for the Caribbean context and supplemented with questions on cervical cancer and HPV/HPV vaccine knowledge and beliefs. Data collection took place online from October 2022 to March 2023. Results: Participants are young, single, well-educated, and have stable financial resources. Over a quarter (26.4%) agreed women with cervical cancer are more isolated in their country. Almost half (47%) of respondents agreed cultural background plays a big part in how they feel about illness and getting well. One in six participants believe women with cervical cancer are treated with less respect than usual by others in their country. Conclusion: Cancer stigma of cervical cancer exists in Jamaica, Trinidad and Tobago, and Grenada. Particularly, cultural background and social norms are closely linked to stigma.
Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
PURPOSE: This study investigated the effect of an isocitrate dehydrogenase 1 (IDH1) mutation (mutIDH1) on the invasion and angiogenesis of human glioma cells.
METHODS: Doxycycline was used to induce the expression of mutIDH1 in glioma cells. Transwell and wound healing assays were conducted to assess glioma cell migration and invasion. Western blotting and cell immunofluorescence were used to measure the expression levels of various proteins. The influence of bone morphogenetic protein 2 (BMP2) on invasion, angiogenesis-related factors, BMP2-related receptor expression, and changes in Smad signaling pathway-related proteins were evaluated after treatment with BMP2. Differential gene expression and reference transcription analysis were performed.
RESULTS: Successful infection with recombinant lentivirus expressing mutIDH1 was demonstrated. The IDH1 mutation promoted glioma cell migration and invasion while positively regulating the expression of vascularization-related factors and BMP2-related receptors. BMP2 exhibited a positive regulatory effect on the migration, invasion, and angiogenesis of mutIDH1-glioma cells, possibly mediated by BMP2-induced alterations in Smad signaling pathway-related factors.After BMP2 treatment, the differential genes of MutIDH1-glioma cells are closely related to the regulation of cell migration and cell adhesion, especially the regulation of Smad-related proteins. KEGG analysis confirmed that it was related to BMP signaling pathway and TGF-β signaling pathway and cell adhesion. Enrichment analysis of gene ontology and genome encyclopedia further confirmed the correlation of these pathways.
CONCLUSION: Mutation of isocitrate dehydrogenase 1 promotes the migration, invasion, and angiogenesis of glioma cells, through its effects on the BMP2-driven Smad signaling pathway. In addition, BMP2 altered the transcriptional patterns of mutIDH1 glioma cells, enriching different gene loci in pathways associated with invasion, migration, and angiogenesis.
Sepsis is a life-threatening state that arises due to a hyperactive inflammatory response stimulated by infection and rarely other insults (e.g., non-infections tissue injury). Although changes in several proinflammatory cytokines and signals are documented in humans and small animal models, far less is known about responses within affected tissues of large animal models. We sought to understand the changes that occur during the initial stages of inflammation by administering intravenous lipopolysaccharide (LPS) to Yorkshire pigs and assessing transcriptomic alterations in the brain, kidney, and whole blood. Robust transcriptional alterations were found in the brain, with upregulated responses enriched in inflammatory pathways and downregulated responses enriched in tight junction and blood vessel functions. Comparison of the inflammatory response in the pig brain to a similar mouse model demonstrated some overlapping changes but also numerous differences, including oppositely dysregulated genes between species. Substantial changes also occurred in the kidneys following LPS with several enriched upregulated pathways (cytokines, lipids, unfolded protein response, etc.) and downregulated gene sets (tube morphogenesis, glomerulus development, GTPase signal transduction, etc.). We also found significant dysregulation of genes in whole blood that fell into several gene ontology categories (cytokines, cell cycle, neutrophil degranulation, etc.). We observed a strong correlation between the brain and kidney responses, with significantly shared upregulated pathways (cytokine signaling, cell death, VEGFA pathways) and downregulated pathways (vasculature and RAC1 GTPases). In summary, we have identified a core set of shared genes and pathways in a pig model of systemic inflammation.
<P>PROBLEM TO BE SOLVED: To provide a medical management system in which medical instruments can be sufficiently effectively utilized even in a medical institution poor in human resources for operating the medical instruments.  <P>SOLUTION: A medical instrument management computer 11 is attached to a medical instrument 10. A host computer 20 is connected to the medical instrument management computer 11 and an assist computer 30 is connected to the host computer 20 respectively via communication line networks. The host computer 20 prepares the operation data of the medical instrument 10 on the basis of data on a person who desires the utilization of the medical instrument 10, and sends these data to the assist computer 30. A medical specialist transmits the operation data from the assist computer 30 to the medical instrument management computer 11 and makes a doctor in charge of operation operate the medical instrument 10. Otherwise, the medical specialist directly operates the medical instrument 10 via the assist computer 30.  <P>COPYRIGHT: (C)2003,JPO
Vinorelbine is a cytotoxic drug. Follow applicable special handling and disposal procedures1.

Exercise caution in handling and preparing the solution of vinorelbine injection. The use of gloves is recommended. If the solution of vinorelbine injection contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water. 

Avoid contamination of the eye with vinorelbine injection. If exposure occurs, flush the eyes with water immediately and thoroughly. 

Discard unused portion.
A new composite material of an open foam substrate and bonded micropackaged active ingredient particles is generated by foam polymerization of a prepolymer phase and an aqueous phase. The foam substrate is an open cell foam for dispensing active ingredient liquids or solids released from the particles. The particles of micropackaged active ingredient liquids or solids are formed with frangible containment walls for breaking and releasing the active ingredient in response to defined stress. The micropackaged active ingredient particles are approximately 400 to 5,000 microns in diameter. The aqueous phase is a pourable and flowable slurry mixture of an aqueous liquid carrier such as water, micropackaged active ingredient particles in the range of 1%-60% by weight of the aqueous phase, and surfactant wetting agent for adjusting the surface tension of the aqueous phase to produce an open cell foam upon polymerization with the prepolymer phase. The prepolymer phase is a hydrophilic polyurethane prepolymer receptive to the aqueous phase for foam polymerization upon mixing. The aqueous phase and prepolymer phase are generally mixed together in a ratio by weight of aqueous phase to prepolymer phase in a range of at least approximately 0.02/1 or greater and preferably 1/1 or greater. Upon foam polymerization, the active ingredient particles are distributed over and intimately bonded to the surfaces of the open foam substrate. The micropackaged particles may constitute any of the available microcontainment systems including microencapsulation system microcapsules and entrapment system microlattices.
Modules, systems, and methods for enabling wireless functionality in electronic devices are disclosed. A module comprises a housing, a plurality of module terminals, a wireless transmitter, a first electronic component, and a power source. The housing is sized to be removably inserted in a power source receptacle of the electronic device. The plurality of module terminals contact a corresponding plurality of device terminals of the electronic device. The first electronic component is operable to receive outbound device data from the electronic device via the module terminal and transmit the outbound device data using the wireless transmitter. The power source is operable to provide power to the electronic device. The method comprises inserting a module in the power source receptacle of the electronic device, receiving outbound device data from the electronic device, and transmitting the outbound device data using the wireless transmitter.